These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21434757)

  • 1. Effects of adalimumab therapy on disease activity and interferon-γ-mediated biochemical pathways in patients with rheumatoid arthritis.
    Kurz K; Herold M; Winkler C; Klotz W; Russe E; Fuchs D
    Autoimmunity; 2011 May; 44(3):235-42. PubMed ID: 21434757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S; McColl G; Wicks IP
    Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab.
    Zikou AK; Argyropoulou MI; Voulgari PV; Xydis VG; Nikas SN; Efremidis SC; Drosos AA
    J Rheumatol; 2006 Feb; 33(2):219-23. PubMed ID: 16465650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased degradation of tryptophan in blood of patients with rheumatoid arthritis.
    Schroecksnadel K; Kaser S; Ledochowski M; Neurauter G; Mur E; Herold M; Fuchs D
    J Rheumatol; 2003 Sep; 30(9):1935-9. PubMed ID: 12966593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis.
    van Eijk IC; Tushuizen ME; Sturk A; Dijkmans BA; Boers M; Voskuyl AE; Diamant M; Wolbink GJ; Nieuwland R; Nurmohamed MT
    Ann Rheum Dis; 2010 Jul; 69(7):1378-82. PubMed ID: 19919943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
    Straub RH; Härle P; Atzeni F; Weidler C; Cutolo M; Sarzi-Puttini P
    J Rheumatol; 2005 Jul; 32(7):1253-8. PubMed ID: 15996060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study.
    Peters MJ; Welsh P; McInnes IB; Wolbink G; Dijkmans BA; Sattar N; Nurmohamed MT
    Ann Rheum Dis; 2010 Jul; 69(7):1281-5. PubMed ID: 19934107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
    Bennett AN; Peterson P; Zain A; Grumley J; Panayi G; Kirkham B
    Rheumatology (Oxford); 2005 Aug; 44(8):1026-31. PubMed ID: 15870150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic responses to change in disease activity during tumor necrosis factor inhibition in patients with rheumatoid arthritis.
    Madsen R; Rantapää-Dahlqvist S; Lundstedt T; Moritz T; Trygg J
    J Proteome Res; 2012 Jul; 11(7):3796-804. PubMed ID: 22574709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
    Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
    Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.